Home›Stock Screener›Jubilant Pharmova

Jubilant Pharmova Share Price Today | Stock Price & Jubilant Pharmova Share Screener

JUBLPHARMA Pharmaceuticals & Biotechnology
Live Share Price NSE
₹933.60
▼ -20.90 (-2.19%)
2026-11-18 00:00:00
Live Share Price BSE
₹934.15
▼ -19.65 (-2.06%)
2026-11-18 00:00:00

As of November 18, 2026, the live Jubilant Pharmova share price (NSE: JUBLPHARMA) is ₹933.60 on NSE and ₹934.15 on BSE, down 2.19% from the previous close, with shares trading between ₹931.00 and ₹953.90 in today's trading session, and a 52-week range of ₹807.65–₹1,108.60. Track Jubilant Pharmova networth to gauge the company's total market size. Use the Jubilant Pharmova stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Jubilant Pharmova opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹2,296 and net income of ₹119, with EBITDA of ₹332, an operating margin of 14.0% and a profit margin of 5.2%.

Jubilant Pharmova Market Cap ₹15,310.10 Cr.
JUBLPHARMA P/E Ratio (TTM) 43.80
Jubilant Pharmova P/B Ratio 2.17
EPS (TTM) ₹25.15
Dividend Yield 0.52%
Debt to Equity 0.48
JUBLPHARMA 52 Week High ₹1108.60
Jubilant Pharmova 52 Week Low ₹807.65
Operating Margin 14.00%
Profit Margin 5.18%
JUBLPHARMA Revenue (TTM) ₹2,296.00
EBITDA ₹332.00
Net Income ₹119.00
Total Assets ₹15,523.00
Total Equity ₹7,096.00

Jubilant Pharmova Share Price Chart

Track the current stock price of Jubilant Pharmova with an interactive chart. Analyse JUBLPHARMA share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Jubilant Pharmova stock quote in one place.

The quote of ₹933.60 sits between the 52-week low of ₹807.65 and the 52-week high of ₹1,108.60, and the latest session moved -2.19% from the previous close.

Jubilant Pharmova Company Profile - Fundamental Screener

Screen Jubilant Pharmova company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for JUBLPHARMA shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, with Shyam S Bhartia listed as chairperson or CEO, and it trades under ISIN INE700A01033.

Business Overview

Jubilant Pharmova Limited is an integrated global pharmaceutical and life sciences company. It operates in segments including Radiopharma, Allergy Immunotherapy, Contract Development and Manufacturing Organisation-Sterile Injectables, Generics, Contract Research, Development and Manufacturing Organisation, and Proprietary Novel Drugs. The company manufactures and supplies Active Pharmaceutical Ingredients, Solid Dosage Formulations, Radiopharmaceuticals, and...more

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals & Biotechnology
Sub-Sector Pharmaceuticals & Biotechnology
Segment E

Identifiers and Leadership

Chairperson/CEO Shyam S Bhartia
ISIN INE700A01033

Jubilant Pharmova Balance Sheet Screener

Screen JUBLPHARMA balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹15,523, up from ₹12,756 in 2025.

Latest statistics put total assets at ₹15,523 and shareholder funds at ₹7,096, with a leverage ratio of 0.48.

Item 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017

Assets

Total Assets 15,523 12,756 11,549 11,157 9,991 8,918 12,522 11,469 9,618 9,041
Current Assets 0 0 0 0 0 0 0 0 0 0
Fixed Assets 6,966 5,176 5,091 5,183 4,871 4,609 6,340 5,648 5,401 5,107

Liabilities

Total Liabilities 0 0 0 0 0 0 0 0 0 0
Current Liabilities 5,888 4,353 4,238 3,993 3,083 3,128 4,299 4,570 3,578 3,968
Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity 7,096 6,239 5,421 5,392 5,316 4,742 5,604 4,809 4,035 3,389
Share Capital 16 16 16 16 16 16 16 16 16 16
Reserves & Surplus 7,077 6,239 5,418 5,383 5,303 4,726 5,588 4,793 4,071 3,421

Jubilant Pharmova Income Statement Screener - Profit & Revenue Analysis

Screen Jubilant Pharmova income statement and profit fundamentals. Analyze JUBLPHARMA quarterly results. Jubilant Pharmova reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For 2026-Mar, revenue was ₹2,296 and net profit was ₹119, equal to earnings per unit of ₹7.55, at an operating margin of 14%.

In that period expenses were ₹1,964, interest cost ₹57 and tax ₹57. The next period listed, 2026-Jun, shows revenue of ₹2,241 and net profit of ₹56.

Item 2026-Mar 2026-Jun 2026-Sept 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar 2024-Jun 2024-Sept 2024-Dec 2023-Mar 2023-Jun 2023-Sept 2023-Dec

Revenue and Expenses

Revenue 2,296 2,241 2,375 1,928 1,891 1,968 2,137 1,764 2,130 1,764 1,823 1,682 1,575 1,686 1,714
Expenses 1,964 1,981 2,130 1,587 1,611 1,631 1,873 1,656 1,480 1,477 1,554 1,459 1,419 1,439 1,459

Operating Costs and Margins

EBITDA 332 260 245 341 280 337 264 108 650 287 269 223 156 247 255
Operating Profit % 14.00% 11.00% 10.00% 17.00% 14.00% 17.00% 12.00% 5.00% 14.00% 15.00% 14.00% 12.00% 9.00% 14.00% 12.00%
Depreciation 117 127 135 95 98 105 121 101 91 91 91 271 90 97 95
Interest 57 54 58 53 49 50 56 73 71 61 56 56 62 66 71

Profit and Earnings

Profit Before Tax 176 86 62 206 154 190 93 -54 500 144 131 -86 25 98 101
Tax 57 30 31 55 52 70 38 8 18 42 30 14 19 36 35
Net Profit 119 56 31 151 103 120 56 -62 482 103 101 -101 6 62 66
EPS 7.55 3.57 1.97 9.71 6.49 7.59 3.52 -3.69 30.44 6.47 6.37 -6.15 0.40 3.94 4.22

Jubilant Pharmova Cash Flow Screener - Liquidity Fundamentals

Screen JUBLPHARMA cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities generated ₹1,227, and net cash flow was an inflow of ₹179.

Over the same period, investing activities used ₹1,143 and financing activities provided ₹95.

Item 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March

Cash from Operations and Investing

Operating Activities 1,227 1,072 971 661 838 1,784 1,543 1,122 1,303 1,269
Investing Activities -1,143 513 -596 -474 -323 -727 -267 -1,018 -614 -465

Financing and Net Cash

Financing Activities 95 -1,453 -433 -157 -33 -1,709 -1,050 657 -901 -686
Net Cash Flow 179 132 -58 30 482 -652 225 761 -212 117

Jubilant Pharmova Shareholding Pattern Screener

See Jubilant Pharmova shareholding pattern with promoter, FII, and DII holdings. Check Jubilant Pharmova promoter holding and ownership changes for JUBLPHARMA on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Mar, promoters held 47.68%, foreign institutions 15.90%, domestic institutions 11.62% and the public 17.57%, spread across 86,347 shareholders.

The shareholder count was 86,347 in 2026-Mar, compared with 82,703 in 2026-Jun.

Item 2026-Mar 2026-Jun 2026-Sept 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar

Promoter Holding

Promoter Holding 47.68% 47.68% 47.68% 50.68% 47.68% 47.68% 47.68% 50.68%

Institutional Investors

FII Holding 15.90% 15.87% 15.38% 17.22% 17.40% 16.57% 15.96% 19.06%
DII Holding 11.62% 12.40% 13.02% 7.05% 9.53% 10.52% 11.22% 3.78%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 17.57% 17.16% 17.04% 17.75% 17.97% 18.02% 17.85% 18.71%
Other Holding 7.23% 6.89% 6.89% 7.31% 7.42% 7.22% 7.29% 7.77%
Shareholder Count 86,347 82,703 82,602 96,526 99,673 93,336 90,133 92,264

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Jubilant Pharmova. Jubilant Pharmova dividend yield can be compared with peers and other stocks in the market.

The latest dividend recorded was ₹5.00 per unit for 2026-March, a yield of 0.52%, compared with ₹5.00 for 2025-March.

Dividends are listed for 10 periods, with the three most recent payouts at ₹5.00, ₹5.00 and ₹5.00 per unit.

Period Dividend Per Share Dividend Yield
2026-March ₹5.00 0.52%
2025-March ₹5.00 0.61%
2024-March ₹5.00 0.56%
2023-March ₹5.00 0.88%
2022-March ₹5.00 1.79%
2021-March ₹5.00 1.29%
2020-March ₹5.00 0.73%
2019-March ₹4.50 1.81%
2018-March ₹3.00 0.45%
2017-March ₹3.00 0.36%

Jubilant Pharmova Stock Index Membership - Nifty & Sensex

See which indices include Jubilant Pharmova stock. Check JUBLPHARMA index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

The company is listed in 14 indices, including BSE 1000.

Among the benchmarks tracked are BSE 1000, BSE INDEX BSE HC, BSE INDEX BSE500, BSE INDEX MSL400.

Complete Index List

BSE 1000
BSE INDEX BSE HC
BSE INDEX BSE500
BSE INDEX MSL400
BSE INDEX SML250
BSE INDEX SMLCAP
NIFTY 500
NIFTY MIDSML 400
NIFTY SMLCAP 250
NIFTY TOTAL MKT
NIFTY500 EQUAL WEIGHT
NIFTY500 LARGEMIDSMALL EQUAL CAP WEIGHTED
NIFTY500 MOMENTUM 50
NIFTY500 MULTICAP

Jubilant Pharmova Market Events Screener - Corporate Actions

Get Jubilant Pharmova corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Jubilant Pharmova stock events that may affect JUBLPHARMA share price, along with derivatives, futures and options activity and sector gainers.

15 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated November 13, 2026, with a record date of November 13, 2026.

It is followed by Annual General Meeting dated August 26, 2026 and Quarterly Result Announcement dated August 10, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-11-13 2026-11-13 Quarterly Result Announcement NA 3.91%
2026-08-26 2026-08-26 Annual General Meeting NA -6.93%
2026-08-10 2026-08-10 Quarterly Result Announcement NA -4.69%
2026-07-24 2026-07-24 Dividend ₹ 5.00 /share -4.03%
2026-05-22 2026-05-22 Quarterly Result Announcement NA 6.91%
2026-02-06 2026-02-06 Quarterly Result Announcement NA 2.93%
2025-10-31 2025-10-31 Quarterly Result Announcement NA 1.90%
2025-08-29 2025-08-29 Annual General Meeting NA -7.13%
2025-07-29 2025-07-29 Quarterly Result Announcement NA -2.98%
2025-07-25 2025-07-25 Dividend ₹ 5.00 /share 29.75%
2025-05-16 2025-05-16 Quarterly Result Announcement NA 1.03%
2025-01-31 2025-01-31 Quarterly Result Announcement NA 1.84%
2024-10-25 2024-10-25 Quarterly Result Announcement NA -9.79%
2024-08-30 2024-08-30 Annual General Meeting NA 8.43%
2024-08-02 2024-08-02 Dividend ₹ 5.00 /share 23.06%

Jubilant Pharmova Competitors Screener - Peer Stocks Comparison

Screen JUBLPHARMA competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 451,771 41.10 61,674 12.69% 11,565 63.60
Divis Laboratories 298,360 90.70 11,067 13.95% 2,568 78.53
Torrent Pharmaceuticals 179,328 84.50 13,886 20.34% 2,138 47.27
Laurus Labs 125,498 98.10 6,868 22.01% 890 69.60
Zydus Life Science 119,700 27.60 27,658 17.64% 5,026 52.34
Dr Reddys Laboratories 115,820 41.70 35,059 3.90% 4,158 70.24
Cipla 112,656 39.40 29,045 2.24% 3,870 54.92
Mankind Pharma 109,622 48.40 14,636 14.85% 1,938 65.43
Aurobindo Pharma 104,569 26.40 34,145 5.56% 3,503 66.06
Lupin 91,156 17.30 29,039 26.75% 5,356 44.92

Jubilant Pharmova Company Announcements - News & Reports Screener

Screen JUBLPHARMA latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated November 19, 2026.

The next most recent announcements are dated November 18, 2026 and November 18, 2026.

Date Update Actions
2026-11-19 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-11-18 Announcement under Regulation 30 (LODR)-Press Release / Media Release -
2026-11-18 Un-Audited Financial Results For The Quarter And Half Year Ended September 30 2026 -
2026-11-18 Board Meeting Outcome for Meeting Held On November 13 2026 -
2026-11-15 Announcement under Regulation 30 (LODR)-Press Release / Media Release -
2026-11-10 Announcement under Regulation 30 (LODR)-Allotment -
2026-11-10 Disclosure Under Regulation 30 And Other Applicable Provisions Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 - Allotment Of Non-Convertible Debentures (Ncds) On A Private Placement Basis-R -
2026-11-02 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-10-30 Board Meeting Intimation for Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Half Year Ended September 30 2026 -
2026-10-23 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-10-22 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-10-21 Shareholder Meeting / Postal Ballot-Notice of Postal Ballot -
2026-10-21 Announcement under Regulation 30 (LODR)-Credit Rating -
2026-10-14 Announcement under Regulation 30 (LODR)-Credit Rating -
2026-10-12 Announcement under Regulation 30 (LODR)-Raising of Funds -
2026-10-12 Board Meeting Outcome for Issuance Of Secured / Unsecured Listed Rated Redeemable Non-Convertible Debentures (Ncds) On Private Placement Basis -
2026-10-08 Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 -
2026-10-07 Board Meeting Intimation for To Consider And Approve Raising Of Funds Through The Issuance Of Non-Convertible Debentures (Ncds) And/Or Such Other Securities As May Be Permitted Under Applicable Laws And To Approve Seeking Shareholders Approval As May Be R -
2026-10-05 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-09-29 Closure of Trading Window -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹933.60, within a 52-week range of ₹807.65 to ₹1,108.60. The P/E ratio is 43.80 and the P/B ratio is 2.17, with earnings per unit of ₹25.15. Market capitalisation stands at ₹15,310.10 Cr and the dividend yield is 0.52%. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the NSE and the BSE. Key statistics were last updated on November 20, 2026. This page covers 10 balance sheet periods, 15 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.